NasdaqCM:CORTPharmaceuticals
A Look At Corcept Therapeutics (CORT) Valuation After The FDA Complete Response Letter On Relacorilant
What triggered the latest move in Corcept Therapeutics (CORT)?
The recent swing in Corcept Therapeutics (CORT) shares traces back to an FDA Complete Response Letter on relacorilant for hypertension secondary to hypercortisolism, which flagged the need for more effectiveness evidence despite pivotal trial endpoints being met.
See our latest analysis for Corcept Therapeutics.
After the FDA setback, Corcept Therapeutics’ 1 day share price return of 2.66% and 7 day return of 7.30% have only...